Taylor & Francis Group
Browse
kcam_a_1766308_sm5365.xlsx (9.47 kB)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer

Download (9.47 kB)
dataset
posted on 2020-05-18, 09:33 authored by Ying Yang, Tingting Lu, Ziming Li, Shun Lu

Aims: The analysis of the online databases revealed that CCND1 expression is correlated with poor prognosis in LSCC. We aimed to explore the function of CCND1 in tumor progression in LSCC.

Main methods: The expression of mRNA was measured using qRT-PCR. Protein expression was assessed by Western blot. Cell migration and invasion were assessed by transwell assay.

Key findings: CCND1 was co-overexpressed with FGFR1 in lung cancer patients. Overexpression of CCND1 promoted LSCC cell proliferation and metastasis. FGFR1 promoted the processes of EMT through AKT/MAPK signaling by targeting CCND1 in FGFR1-amplification cell lines.

Significance: IIn conclusion, our study demonstrated the regulatory mechanism between CCND1 and FGFR1 in FGFR1 amplified LSCC. Co-targeting CCND1 and FGFR1 could provide greater clinical benefits.

Funding

The National Key R&D Program of China (2016YFC1303300 to S. Lu), Shanghai Chest Hospital Project of Collaborative Innovation (YJXT20190105, YJXT20190209, to S.L and Z.L.), the National Natural Science Foundation of China (81672272 to S. Lu and 81773115 to W. Xia), the Key project of Shanghai Health & Family Planning (201540365 to S. Lu), Shanghai Municipal Science & Technology Commission Research Project (17431906103 to S. Lu), Shanghai Scientific Research Projects (14140902800 to S. Lu), and AstraZeneca Research Funding. Clinical Research Plan of SHDC (16CR3005A to S. L.), Shanghai Science and Technology Commission guidance projects (18411968200 to Z.L.), Medical-Engineering Joint Funds of Shanghai Jiao Tong University YG2017MS81 (to Z.L.), Shanghai Youth Top Talent Project (to Z.L.).Drug: AZD4547 from AstraZeneca Pharmaceutical Company.

History